The important aspect to see while treating tumor patients with MET inhibitor is that tumor derived tumor necrosis factor-α (TNF-α) or any other inflammatory stimuli enhances the MET activation in human neutrophils and leads to their transmigration across an activated endothelium and releases free radicals, which can inhibit the cancer cell growth [76]. Here, TNF is linked to cancer.